Search Results

The LINQ II ICM is an insertable automatically-activated and patient activated monitoring system that records subcutaneous ECG and is indicated in adult patients, and in pediatric patients who are at least 2 years old, in the following cases:

• · patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
• patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachyarrhythmia, bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event. LINO II ICM includes the following accessories: LINQ II Tool Kit Model LNQ22TK, Reveal LINQ™ Mobile Manager Model MSW002, Device Command Library Model 2692, Instrument Command Library Model 2691, and AccuRhythm AI ECG Classification System Models ZA400, ZA410, ZA420 and CareLink SmartSync LINQ II ICM Application Model D00U024. New to the LINQ II ICM system is the CareLink SmartSync LINQ II Platform Application Model D00U027.

I am sorry, but based on the provided text, I cannot extract any information about the acceptance criteria for device performance, a study proving the device meets acceptance criteria, sample sizes used, data provenance, number of experts, adjudication methods, MRMC comparative effectiveness studies, standalone performance, type of ground truth, or training set details.

The document discusses the substantial equivalence of the LINQ II Insertable Cardiac Monitor (ICM) when used with the CareLink SmartSync LINQ II Platform Application to a predicate device. It states that design verification and validation were performed to ensure the application met design requirements and established performance criteria, and that "all test executions resulted in a status of Passed" and "All results met the criteria in the Validation Plan." However, it does not specify what those performance criteria or validation plan criteria were, nor does it provide details about any specific studies conducted to establish device performance in terms of diagnostic accuracy or clinical effectiveness.

The document focuses on regulatory approval based on substantial equivalence to a predicate device, and the testing mentioned appears to be primarily related to software and system design verification and validation, rather than a clinical performance study with specific acceptance criteria that would include the metrics you've asked for (e.g., sensitivity, specificity, accuracy against a ground truth from experts).

Ask a specific question about this device

The LINQ II ICM is an insertable automatically-activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in adult patients who are at least 2 years old, in the following cases:

· patients with clinical syndromes or situations at increased risk of cardiac arrhythmias

· patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachyarrhythmia, bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event. LINO II ICM includes the following accessories: LINO II Tool Kit Model LNO22TK, Reveal LINO™ Mobile Manager Model MSW002. Device Command Library Model 2692. Instrument Command Library Model 2691, and AccuRhythm AI ECG Classification System Models ZA400, ZA410, and ZA420. New to the LINO II ICM system is the CareLink SmartSync LINO II ICM Application Model D00U024.

Based on the provided text, the device in question is the LINQ II Insertable Cardiac Monitor (ICM) and its associated CareLink SmartSync LINQ II ICM Application. The document describes a 510(k) submission, which focuses on demonstrating substantial equivalence to a predicate device rather than presenting a de novo clinical study with specific acceptance criteria related to disease detection performance.

Therefore, much of the requested information regarding "acceptance criteria and the study that proves the device meets the acceptance criteria" in the context of a typical AI/ML medical device performance study (e.g., sensitivity, specificity, clinical accuracy) is not explicitly provided or applicable in this regulatory submission. This submission primarily addresses changes to a software application used with an existing, cleared device and demonstrates that these changes do not alter the existing device's safety, effectiveness, or indications for use.

However, I can extract information related to the design verification and validation testing that was performed to ensure the CareLink SmartSync LINQ II ICM Application meets its specified requirements and performs as intended.

Here's a breakdown of the requested information, with clarification where the document does not provide details relevant to a "performance study" as typically understood for AI algorithms:

1. A table of acceptance criteria and the reported device performance

The document states:

• "Software and system design verification were completed to ensure the design output meets specifications outlined in the design inputs. The CareLink SmartSync LINQ II ICM Application meets the functionality per the requirements and all test executions resulted in a status of Passed."
• "System validation testing and analysis were completed to ensure the CareLink SmartSync LINO II ICM Application meets design input requirements under actual or simulated use conditions. All results met the criteria in the Validation Plan."

This indicates that the acceptance criteria were the fulfillment of design input requirements and specifications, and the reported performance is that all tests "Passed" and "All results met the criteria in the Validation Plan."

Specific performance metrics (e.g., sensitivity, specificity, accuracy for arrhythmia detection) of the LINQ II ICM itself are not presented in this document, as the submission is for the accompanying software application's compatibility and functionality, not a re-evaluation of the ICM's core arrhythmia detection performance.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Sample Size for Test Set: Not specified. The document mentions "Software and system design verification" and "System validation testing and analysis," but does not provide details on the number of cases, patient data, or exact nature of the "test sets" used. This testing appears to be focused on software functionality and connectivity rather than clinical data analysis with a specific sample of patient ECGs.
• Data Provenance: Not specified. Given the nature of the submission (software update/compatibility), it's highly likely that the testing involved internal simulated data or a small set of real-world scenarios to confirm software functionality, not a large-scale clinical dataset from a specific country or with a specific recruitment methodology.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

• Not applicable/Not specified. This information is typically relevant for studies evaluating the clinical performance of a diagnostic algorithm (e.g., how well it detects a disease compared to expert consensus). This 510(k) submission is for the software application's functionality with an existing device, not a re-evaluation of the device's diagnostic performance for arrhythmia. Therefore, "ground truth" in the clinical diagnostic sense with expert readers is not described.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

• Not applicable/Not specified. As above, this applies to clinical performance studies, not primarily to software functionality verification and validation.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• No. An MRMC study was not described or implied in this submission. This type of study investigates the impact of AI assistance on human reader performance, which is not the focus of this 510(k) given its scope (addition of a new connectivity application).

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Not explicitly described in terms of diagnostic performance metrics for an "algorithm." The LINQ II ICM itself has embedded algorithms for arrhythmia detection, but this submission pertains to the CareLink SmartSync application used for data transmission and interaction. The original LINQ II ICM was cleared with its own performance data, which is not detailed here. The "standalone" performance described for the CareLink SmartSync app is its ability to meet "design input requirements" and "functionality per requirements," which are software engineering quality metrics, not clinical diagnostic performance metrics.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

• For the LINQ II ICM's core arrhythmia detection (which is not the subject of this specific 510(k)'s new testing): This information would typically be established during its initial clearance via clinical studies correlating ECG recordings with expert interpretation or clinical outcomes. However, this submission does not detail how the ground truth for the ICM's performance was established.
• For the CareLink SmartSync Application: The "ground truth" was likely defined by the software's functional specifications and design requirements. Successful completion of automated and manual tests demonstrating that the software behaved as designed would constitute meeting its "ground truth" (i.e., it performs the specified functions correctly). No mention of expert clinical consensus or pathology data for this application's testing is made.

8. The sample size for the training set

• Not applicable/Not specified. This submission does not describe an AI/ML model for arrhythmia detection that would require a "training set." The CareLink SmartSync Application is a software interface, not an independent diagnostic AI algorithm.

9. How the ground truth for the training set was established

• Not applicable/Not specified. As above, no training set for an AI/ML model is described.

In summary: This 510(k) submission is focused on demonstrating that the CareLink SmartSync LINQ II ICM Application (a new software component for connectivity and data transmission) when used with the existing LINQ II Insertable Cardiac Monitor maintains substantial equivalence to the predicate device. The "acceptance criteria" and "study" described are primarily related to software verification and validation testing to ensure the new application functions as intended and does not introduce new safety or performance concerns, rather than a clinical performance study of a diagnostic AI algorithm.

Ask a specific question about this device

The LINQ II ICM is an insertable automatically activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in adult patients, and in pediatric patients who are at least 2 years old, in the following cases:

· Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias

· Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

The LINO II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachvarrhythmia. bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event. LINQ II ICM includes the following medical accessories: LINQ Tool Kit Model LNQ22TK, Patient Assistant Model PA97000, Reveal LINQ™ Mobile Manager Model MSW002 with patient connector Model 24967, Device Command Library Model 2692, Instrument Command Library Model 2691, and the Zelda (AccuRhythm) AI ECG Classification System Models ZA400, ZA410, and ZA420.

This document describes the 510(k) premarket notification for the LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22, which is being cleared for expanded indications for use. The submission focuses on expanding the existing indications to include the pediatric patient population and expanding MRI conditions for use.

Here's the information extracted:

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't provide a specific table in the typical format of acceptance criteria with corresponding performance metrics for the device itself as a diagnostic tool. Instead, the "acceptance criteria" discussed are related to design validation and regulatory compliance for the expanded indications.

2. Sample Size Used for the Test Set and Data Provenance:

The document describes a retrospective clinical evaluation.

• Sample Size: Not explicitly stated as a numerical sample size. It refers to an evaluation of "published literature, post-market surveillance data, and studies," suggesting a review of existing data rather than collection of new patient data for a specific test set.
• Data Provenance: Retrospective, derived from "published literature, post-market surveillance data, and studies." No specific country of origin is mentioned, but post-market surveillance data would likely span various regions where the device was previously marketed.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

Not applicable. The study was a retrospective clinical evaluation of existing data (published literature, post-market surveillance, and studies) to assess safety and effectiveness in the pediatric population for expanded indications. It did not involve establishing a new ground truth for a test set through expert adjudication of individual cases.

4. Adjudication Method for the Test Set:

Not applicable. As noted above, this was a retrospective review of existing data, not a study involving expert adjudication of a new test set.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:

No. The document does not mention an MRMC comparative effectiveness study where human readers improve with or without AI assistance. The submission is for an expanded indication for an existing device, not a new AI-assisted diagnostic tool comparison.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done:

While the LINQ II ICM includes the "Zelda (AccuRhythm) AI ECG Classification System," this submission focuses on the expanded indications for use of the overall device (LINQ II ICM) for pediatric patients and MRI conditions. It does not provide details on standalone performance studies specifically for the AI component within this context. The core device functions to automatically detect arrhythmias, but the focus of this particular 510(k) is the hardware's expanded use.

7. The Type of Ground Truth Used:

For the clinical evaluation: The "ground truth" for assessing safety and effectiveness in the pediatric population was based on existing published literature, post-market surveillance data, and previous studies. This implies that clinical outcomes and established diagnostic criteria within those existing data sources served as the basis for evaluation.

8. The Sample Size for the Training Set:

Not applicable. This submission concerns the expansion of indications for an existing device, not the development or training of a new algorithm. If the "Zelda (AccuRhythm) AI ECG Classification System" was trained, information about its training set is not provided in this document as it pertains to the overall device's market clearance.

9. How the Ground Truth for the Training Set Was Established:

Not applicable, as this submission does not detail the training of a new algorithm.

Ask a specific question about this device

The LINQ II ICM is an insertable automatically-activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:
• patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
• patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachyarrhythmia, bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event. LINQ II ICM includes the following accessories: LINQ Tool Kit Model LNQ22TK, Reveal LINQTM Mobile Manager Model MSW002, Device Command Library Model 2692, and Instrument Command Library Model 2691. New to the LINO II ICM system is the Zelda AI ECG Classification System Models ZA400. ZA410. ZA420. included in this submission.

The provided text describes the 510(k) summary for the Medtronic LINQ II Insertable Cardiac Monitor (ICM) when used with the new Zelda AI ECG Classification System. While a general overview of testing is provided, it does not contain the detailed acceptance criteria or the specific study results demonstrating how the device met those criteria, particularly in the format of a table of acceptance criteria and reported device performance.

The document states:

• "Performance validation testing and analysis were completed to ensure the algorithms were able to reduce false alerts from ICM detected AF and Pause episodes while retaining true alerts. All results met or exceeded the criteria in the Validation Plan."
• "The results of the testing met the design requirements and specified acceptance criteria and did not raise new safety or performance issues."

However, the specific numerical acceptance criteria (e.g., minimum sensitivity, minimum specificity, maximum false alert rates) and the corresponding achieved performance values are not listed. Also, details regarding the sample size, data provenance, expert qualifications, and ground truth establishment for the test set are largely absent.

Therefore,Based on the provided text, I cannot provide a complete answer to your request as the specific detailed information on acceptance criteria and study results (like a table of performance metrics, sample sizes for test sets, number of experts, and adjudication methods) is not included in this 510(k) summary. The document states that testing was performed and met criteria, but it does not specify what those criteria or results were.

Here's what can be inferred and what information is missing:

Information Present or Inferable:

• Device Name: LINQ II Insertable Cardiac Monitor with Zelda AI ECG Classification System
• Purpose of Zelda AI: To reduce false alerts from ICM detected AF and Pause episodes while retaining true alerts.
• Study Type (Implied): Performance validation testing to ensure the algorithms met design requirements and performance criteria.
• Ground Truth (Training): The document mentions "re-training the algorithm on data labeled following the original protocol and data labeled following an alternate protocol." This implies that the training data had labels, but the method of establishing these labels is not detailed.
• Ground Truth Type (Implied): Given the context of ECG classification for arrhythmias, the ground truth would likely be established by qualified experts (e.g., cardiologists, electrophysiologists) reviewing the ECGs.
• No Multi Reader Multi Case (MRMC) Study: The document does not mention any comparative effectiveness study involving human readers. The focus of the Zelda AI is on improving the device's automatic classification, not necessarily on human reader assistance.
• Standalone Performance: The AI system is designed to improve the LINQ II ICM's automatic detection, suggesting a focus on standalone (algorithm-only) performance in reducing false alerts.
• Predetermined Change Control Plan (PCCP): Future algorithm improvements are planned under a PCCP, with methods for re-training algorithms and defined assessment metrics, acceptance criteria, and statistical methods for performance testing of proposed changes. This suggests a robust framework for future validation, but doesn't detail the initial validation.

Missing Information (Crucial for a complete answer):

1. Table of Acceptance Criteria and Reported Device Performance: This is the most significant missing piece. The document states "All results met or exceeded the criteria in the Validation Plan," but the numerical criteria and the actual performance metrics are not given.
2. Sample Sizes Used for the Test Set: This critical detail is not provided.
3. Data Provenance for Test Set: Not specified (e.g., country of origin, retrospective/prospective).
4. Number of Experts Used for Ground Truth (Test Set): Not specified.
5. Qualifications of Experts for Ground Truth (Test Set): Not specified.
6. Adjudication Method for Test Set Ground Truth: Not specified.
7. Effect Size of Human Readers Improvement (for MRMC, if applicable): Not applicable as an MRMC study is not mentioned.
8. Sample Size for the Training Set: Not specified.
9. How Ground Truth for Training Set was Established: Broadly, it states "data labeled following the original protocol and data labeled following an alternate protocol," but specifics on expert involvement or adjudication are missing.

To answer your request fully, you would need to consult a more detailed technical report or study appended to the 510(k) submission, which is typically not publicly available in this summary format.

Ask a specific question about this device

The LINQ II ICM is an insertable automatically-activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

• patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
• patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

The device has not been tested specifically for pediatric use.

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachyarrhythmia, bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event.

The provided text is a 510(k) Summary for the Medtronic LINQ II Insertable Cardiac Monitor. This document focuses on demonstrating substantial equivalence to a predicate device after a software update (RAMware). It does not contain a comprehensive study detailing the initial performance of the device against specific acceptance criteria for arrhythmia detection, but rather confirms that the software update did not negatively impact the previously established performance.

Therefore, much of the requested information regarding acceptance criteria and a study proving the device meets these criteria for the core functionality of arrhythmia detection is not present in this specific document. The document only states that "The results of the above verification and validation testing met the specified acceptance criteria and did not raise new safety or performance issues." after a RAMware update.

However, I can extract what is implied and what minimal information is available about the impact of the RAMware update:

1. A table of acceptance criteria and the reported device performance

Based on the provided text, the acceptance criteria and performance reported relate specifically to the RAMware update and its impact on battery reporting and rejection parameters, not the overall arrhythmia detection performance of the LINQ II ICM.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not provided in the document. The document refers to "device verification and system validation testing" but does not specify sample sizes or data provenance.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not provided in the document.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not provided in the document.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC study is not mentioned in this document. This document is focused on a software update for an existing device, not an AI-assisted interpretation system. The LINQ II is an "automatically-activated and patient-activated monitoring system that records subcutaneous ECG" and is an "arrhythmia detector and alarm," implying automated detection rather than human reader improvement with AI.

6. If a standalone (i.e. algorithm only, without human-in-the-loop performance) was done

The LINQ II ICM is inherently a standalone device in its primary detection function ("automatically-activated"). The document does not describe a separate standalone performance study in the context of this software update, but rather confirms the continued proper functioning of the device as a standalone detector after the update.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

This information is not provided in the document. For an arrhythmia detector, ground truth would typically involve expert-reviewed ECGs or confirmed clinical diagnoses. However, for this submission, the "ground truth" for the RAMware update likely refers to engineering specifications and expected behavior for battery reporting and rejection parameters.

8. The sample size for the training set

This information is not applicable/provided. The document describes a "RAMware update" to existing firmware, implying a software modification rather than a new machine learning model requiring a dedicated training set.

9. How the ground truth for the training set was established

This information is not applicable/provided for the reasons stated in point 8.

Ask a specific question about this device

The LINQ II ICM is an insertable automatically-activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:
• patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
· patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia
The device has not been tested specifically for pediatric use.

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device that continuously monitors a patient's ECG and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient-initiated activation or markings. The device is designed to automatically record the occurrence of an episode of arrhythmia in a patient. Note: Arrhythmias are classified as tachyarrhythmia, bradyarrhythmia, pause, atrial tachyarrhythmia, or atrial fibrillation. Patients may also manually record symptoms. In order to manually record symptoms, the patient will also need either the MyCareLink Heart App (patient app on mobile device) or the Patient Assistant Model PA97000. The patient can use the MyCareLink Heart App or the Patient to manually record his or her cardiac rhythm while experiencing or immediately after a symptomatic event. LINQ II ICM and this submission includes the following accessories: LINO Tool Kit Model LNO22TK, Reveal LINQTM Mobile Manager Model MSW002, Device Command Library Model 2692, and Instrument Command Library Model 2691.

It appears you've provided a 510(k) summary for the Medtronic LINQ II Insertable Cardiac Monitor (ICM), which outlines the device's technical characteristics, indications for use, and a summary of testing performed to demonstrate substantial equivalence to a predicate device.

However, this document does not contain the specific details about the acceptance criteria and the study proving the device meets those criteria in the format you've requested regarding AI/algorithm performance. The information provided heavily focuses on regulatory aspects, engineering verification (mechanical, electrical, EMC, sterilization, biocompatibility, MRI compatibility, human factors, security), and software validation (firmware, regression, system design). While it mentions "Sensing and detection performance validation," it does not break down the specific performance metrics (like sensitivity, specificity, accuracy for arrhythmia detection), the study design used for that validation (e.g., test set demographics, ground truth establishment, expert adjudication), or whether this involved a comparative effectiveness study with human readers (MRMC).

The document states: "The LINQ II ICM includes minor changes to enhance the arrhythmia detection algorithms and diagnostics which include pause detection and PVC detector." However, it does not provide the performance data for these enhanced algorithms or a study design to assess their performance against acceptance criteria.

Therefore, based solely on the provided text, I cannot complete your request for a table of acceptance criteria and reported device performance related to the detection algorithm's diagnostic accuracy, nor can I answer questions about:

• Sample size and data provenance for the test set of the algorithm's diagnostic performance.
• Number of experts and their qualifications for ground truth establishment.
• Adjudication method for the test set.
• MRMC comparative effectiveness study results (effect size of human reader improvement with AI).
• Standalone algorithm performance metrics.
• Type of ground truth used for algorithm performance.
• Sample size for the training set.
• How ground truth for the training set was established.

The document primarily focuses on establishing substantial equivalence to a predicate device, meaning the new device's safety and effectiveness are comparable to a legally marketed device. This often involves demonstrating that changes do not introduce new safety or efficacy concerns and that the device performs as intended in typical engineering and regulatory verification tests. It does not typically include a detailed clinical diagnostic accuracy study of an AI algorithm in the way your prompt describes, especially one that would involve human-in-the-loop performance studies like MRMC.

To answer your question thoroughly, I would need a different type of document, such as a detailed clinical study report specifically focused on the performance of the "arrhythmia detection algorithms and diagnostics" mentioned.

Ask a specific question about this device